Natural history of nonfunctioning pituitary macroadenomas followed without intervention: A retrospective cohort study. 2023

Irit Ayalon-Dangur, and Eyal Robenshtok, and Hadar Duskin-Bitan, and Gloria Tsvetov, and Alex Gorshtein, and Amit Akirov, and Ilan Shimon
Division of Endocrinology and Metabolism, Rabin Medical Center, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

The treatment strategy for nonfunctioning pituitary adenomas (NFPA) includes surgery, radiotherapy, medical treatment, or follow-up. Prior series of patients with NFPAs followed without intervention include small numbers of patients with macroadenomas. This study investigated the natural history of patients with macroadenomas followed without treatment. Retrospective cohort study included patients>18 years, with a diagnosis of NFPA ≥ 10 mm who were naïve to surgery or medical treatment and followed more than 12 months after diagnosis. Patients with chiasmal threat were excluded. Follow-up terminated if the patient underwent surgery, received cabergoline or was lost to follow-up. Data collected included evaluation of tumour characteristics and size by MRI, symptoms including visual disturbances, and hormonal levels. Tumour growth was defined as maximal diameter increase of ≥2 mm. The cohort included 49 patients (30 males, mean age 68.0 ± 12.0 years). At diagnosis, the average tumour size was 17.8 ± 5.9 mm. Mean follow-up time was 4.9 ± 4.9 years. Increase in tumour size occurred in 16 patients (33%), with an average growth of 5.1 ± 4.4 mm. Reduction in tumour size occurred in 10 patients (20%), with a mean decrease of 3.5 ± 1.3 mm. Twenty-three patients remained with stable tumours. Overall, 33 patients (67%) were observed without any intervention; 3 patients were operated and 13 were treated with cabergoline. None of the parameters including age, gender, baseline tumour size, invasiveness, visual disturbances, or hypopituitarism at diagnosis, predicted tumour growth. Observation of NFPAs without surgery or medical therapy is a reasonable approach in selected patients. In our study, no parameter predicted tumour growth.

UI MeSH Term Description Entries
D007018 Hypopituitarism Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions. Adenohypophyseal Hyposecretion,Anterior Pituitary Hyposecretion Syndrome,Sheehan Syndrome,Simmonds Disease,Hyposecretion Syndrome, Anterior Pituitary,Hyposecretion, Adenohypophyseal,Pituitary Insufficiency,Postpartum Hypopituitarism,Postpartum Panhypopituitarism,Postpartum Pituitary Insufficiency,Sheehan's Syndrome,Simmonds' Disease,Disease, Simmonds,Hypopituitarism, Postpartum,Insufficiency, Pituitary,Panhypopituitarism, Postpartum,Pituitary Insufficiency, Postpartum,Sheehans Syndrome,Simmond's Disease,Syndrome, Sheehan,Syndrome, Sheehan's
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077465 Cabergoline An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE. 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea,1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate,Cabaser,Cabaseril,Cabergoline Diphosphate,Dostinex,FCE 21336,FCE-21336,Galastop
D000236 Adenoma A benign epithelial tumor with a glandular organization. Adenoma, Basal Cell,Adenoma, Follicular,Adenoma, Microcystic,Adenoma, Monomorphic,Adenoma, Papillary,Adenoma, Trabecular,Adenomas,Adenomas, Basal Cell,Adenomas, Follicular,Adenomas, Microcystic,Adenomas, Monomorphic,Adenomas, Papillary,Adenomas, Trabecular,Basal Cell Adenoma,Basal Cell Adenomas,Follicular Adenoma,Follicular Adenomas,Microcystic Adenoma,Microcystic Adenomas,Monomorphic Adenoma,Monomorphic Adenomas,Papillary Adenoma,Papillary Adenomas,Trabecular Adenoma,Trabecular Adenomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

Irit Ayalon-Dangur, and Eyal Robenshtok, and Hadar Duskin-Bitan, and Gloria Tsvetov, and Alex Gorshtein, and Amit Akirov, and Ilan Shimon
December 2023, Endocrine connections,
Irit Ayalon-Dangur, and Eyal Robenshtok, and Hadar Duskin-Bitan, and Gloria Tsvetov, and Alex Gorshtein, and Amit Akirov, and Ilan Shimon
December 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
Irit Ayalon-Dangur, and Eyal Robenshtok, and Hadar Duskin-Bitan, and Gloria Tsvetov, and Alex Gorshtein, and Amit Akirov, and Ilan Shimon
March 2017, Journal of neurosurgery,
Irit Ayalon-Dangur, and Eyal Robenshtok, and Hadar Duskin-Bitan, and Gloria Tsvetov, and Alex Gorshtein, and Amit Akirov, and Ilan Shimon
July 2016, Journal of neurosurgery,
Irit Ayalon-Dangur, and Eyal Robenshtok, and Hadar Duskin-Bitan, and Gloria Tsvetov, and Alex Gorshtein, and Amit Akirov, and Ilan Shimon
April 2008, Nederlands tijdschrift voor geneeskunde,
Irit Ayalon-Dangur, and Eyal Robenshtok, and Hadar Duskin-Bitan, and Gloria Tsvetov, and Alex Gorshtein, and Amit Akirov, and Ilan Shimon
January 2020, Neuroendocrinology,
Irit Ayalon-Dangur, and Eyal Robenshtok, and Hadar Duskin-Bitan, and Gloria Tsvetov, and Alex Gorshtein, and Amit Akirov, and Ilan Shimon
October 2008, The Journal of clinical endocrinology and metabolism,
Irit Ayalon-Dangur, and Eyal Robenshtok, and Hadar Duskin-Bitan, and Gloria Tsvetov, and Alex Gorshtein, and Amit Akirov, and Ilan Shimon
September 2018, Journal of neurosurgery,
Irit Ayalon-Dangur, and Eyal Robenshtok, and Hadar Duskin-Bitan, and Gloria Tsvetov, and Alex Gorshtein, and Amit Akirov, and Ilan Shimon
August 2010, European journal of endocrinology,
Irit Ayalon-Dangur, and Eyal Robenshtok, and Hadar Duskin-Bitan, and Gloria Tsvetov, and Alex Gorshtein, and Amit Akirov, and Ilan Shimon
July 2021, Endocrine,
Copied contents to your clipboard!